Because macular telangiectasia is considered a fairly rare condition, there is still much we don’t fully understand. We do know that some patients may only need careful monitoring and may not need ...

The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

Ophthalmologists must take measures to avoid misdiagnosing age-related macular degeneration and consider mimics of the ...

Open label extension initiated with 17 participants rolling over to date in the U.S., U.K., and European Union. Participants ...

You may need to treat a cut in your mouth after playing sports, biting your cheek while eating, or due to another common injury encountered in day-to-day life. Bleeding, along with symptoms of pain ...

“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

It can also leave you vulnerable to various skin infections, she says. In case you missed:How you treat dry skin can also prevent it. Here’s how to do both. “Eczema is something that's chronic.

Mary Kay Koenig from UTHealth Houston with a discussion focused on addressing the high unmet need in Ataxia-Telangiectasia ... detail current symptomatic treatment approaches for patients with ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

including for the potential treatment of Ataxia-Telangiectasia (A-T) and other potential indications; the strategic development path for EryDex; planned regulatory agency submissions and clinical ...